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Background: Despite the consistent relationship between serum γ-glutamyltransferase (GGT) and type 2 diabetes
(T2D), one unsolved issue is the role of serum GGT in the well-known association between obesity and T2D. This
study was performed to investigate whether the association between body mass index (BMI) and impaired fasting
glucose (IFG) differed depending on serum GGT levels within the normal range.
Methods: Study subjects were 2,424 men and 3,652 women aged ≥ 40, participating in the Fifth Korean National
Health and Nutrition Examination Survey. Serum GGT levels within the normal range were classified into
gender-specific tertiles.
Results: Among men and women belonging to the lowest tertile of serum GGT, BMI showed statistically
non-significant weak associations with the risk of IFG. However, among persons in the highest tertile of serum
GGT, the risk of IFG was 3 − 4 times higher among persons with BMI ≥ 25 kg/m2 than those with BMI < 23 kg/m2
(Pinteraction = 0.032 in men and 0.059 in women).
Conclusions: The well-known strong association between BMI and IFG was observed mainly among persons with
elevation of serum GGT to certain physiological levels, suggesting a critical role of serum GGT in the pathogenesis
of IFG. This finding has an important clinical implication because serum GGT can be used to detect high-risk
obese persons.
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Serum γ-glutamyltransferase (GGT) within the normal
range has emerged as an important predictor of type 2
diabetes (T2D) among various populations [1-5]. How-
ever, the role of serum GGT in the well-known association
between obesity and T2D is still unclear. Some epidemio-
logical studies have demonstrated statistically significant* Correspondence: lee_dh@knu.ac.kr
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unless otherwise stated.and borderline significant interactions between serum
GGT and obesity in relation to the risk of T2D [6-8].
Importantly, even little association between obesity and
T2D among persons in the very low normal range of
serum GGT were reported in previous studies [7,8]. These
findings suggest that the elevation of serum GGT to
certain physiological levels is a prerequisite condition for
obesity to increase the risk of T2D.
However, the findings on the interactions between
serum GGT and obesity from previous epidemiological
studies were not consistent; some studies failed to reach
statistical significance with multiplicative interaction terms
[3,5,9,10]. In addition, when gender-specific analyses were
performed, the meaningful interactions were demonstratedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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required to investigate the possible interaction between
serum GGTand obesity associated with the risk of T2D.
In this study, we hypothesized that if there truly were
interactions between serum GGT and obesity in relation
to the risk of T2D, the pattern might be observed more
clearly among individuals with prediabetes. As patients
with T2D are generally advised to lose weight [11] and
serum GGT is also related to a change in body weight
[12], the results could be diluted or distorted with T2D
as the primary outcome of interest. Thus, this study was
performed to investigate whether there were interactions
between serum GGT within the normal range and obesity
in association with the risk of impaired fasting glucose
(IFG), especially focusing on the possibility of little rela-
tionship between obesity and IFG among persons with a




This study analyzed data from the Fifth Korea National
Health and Nutrition Examination Survey (KNHANES
V) conducted by the Korea Centers for Disease Control
and Prevention (KCDC) from 2010 − 2011. KNHANES
V used stratified, multistage clustered sampling in order
to collect a sample representing the Korean population.
After we stratified the population first according to
province and then to types of houses, we extracted 192
primary sampling units. Among the extracted sampling
units, we extracted 20 houses per each sampling unit by
systematic sampling. Specifically, 8,958 subjects were
included in 2010 with a participation rate of 81.9%, and
8,518 subjects were included in 2011 with a participation
rate of 80.4% [13]. Among 7,017 subjects who were over
40 years old with normal serum GGT (serum GGT < 73
U/L in men and < 48 U/L in women) [14] and with
information on diabetic status, we excluded persons with
physician-diagnosed diabetes (including the use of diabetic
medication) (n = 780), fasting blood glucose ≥ 126 mg/dL
(n = 551), or missing information on BMI (n = 15). The
final sample sizes were 2,424 men and 3,652 women. This
study was reviewed and approved by the Institutional
Review Board of KCDC (IRB No. 2010-02CON-21-C,
2011-02CON-06-C), and written informed consent was
obtained from all subjects.
Measurements
KNHANES V consisted of a health interview survey, a
health examination survey, and a nutrition survey. The
data for the health interview and nutrition surveys were
collected through individual interviews. Each partici-
pant’s serum was collected after overnight fasting. The
samples were transported to the core laboratory andanalyzed within 24 hours after collection. Serum glucose
and serum GGT were analyzed using the Hitachi 7600
analyzer. Height was measured in units of 1 millimeter
(mm), and body weight was measured in units of 0.1 kg
using an automatic instrument.
Statistical analysis
KNHANES V was designed as a complex sample, and
data analysis considering stratification, cluster, and weight
was employed. In this study, we defined IFG as fasting
serum glucose between 100 mg/dL and 126 mg/dL.
BMI was classified into three categories (<23, 23–25,
and > 25 kg/m2), and serum GGT was categorized into
gender-specific tertiles. Cutoff points were 22 U/L and 34
U/L in men and 14 U/L and 19 U/L in women. Rather
than use continuous forms of BMI and serum GGT, we
elected to categorize these variables to make the inter-
pretation of results easier to comprehend and compare to
previous research.
First, we examined the associations of IFG with serum
GGT or BMI, not considering the possible interaction
between GGT and BMI. Next, we analyzed the relationship
between BMI and IFG after stratification by serum GGT
into gender-specific tertiles. Analyses were adjusted for
age, alcohol consumption (daily alcohol intake amount),
smoking status (current smoker, former smoker, or never
smoker), pack-years of cigarette smoking, and physical
activity (frequency of days with moderate or vigorous exer-
cise during the previous week). To evaluate the possible
interaction between BMI and serum GGT, the multiplica-
tive interaction term of the three categories of BMI and
the gender-specific tertiles of serum GGT was included
in the multiple logistic regression models. SAS version
9.3 (SAS, Inc., Cary, NC, USA) was used for all statistical
analyses.
Results
The general characteristics of the study subjects are
shown in Table 1. Men and women with high normal
serum GGT were more obese and included more current
smokers and more current drinkers.
Table 2 shows the associations of IFG with serum
GGT or BMI. The risk of IFG was 2 − 3 times higher
among men and women with serum GGT belonging to
the 3rd tertile of the normal range after adjusting for
age, smoking, alcohol intake, and physical activity. Fur-
ther adjustment for BMI did not materially change the
association between serum GGT and IFG. Associations
between BMI and IFG were also observed in men and
women. Adjusted ORs by tertile of GGT were 1.0, 2.0,
and 2.7 in men and 1.0, 1.7, and 2.8 in women (P for
trend < 0.001 for both genders).
In Table 3, we present the associations between BMI
and IFG depending on serum GGT levels in the normal
Table 1 General characteristics of study participants by γ-glutamyltransferase (GGT) tertiles
Tertiles of serum GGT p
Tertile 1 (0 ~ 22 U/L) Tertile 2 (23 ~ 34 U/L) Tertile 3 (35 ~ 73 U/L)
Men (n = 2424) N = 822 N = 800 N = 802
Age (years) 56.2 ± 0.5 54.0 ± 0.5 52.6 ± 0.4 <0.001
Body mass index (kg/m2) 22.8 ± 0.1 24.1 ± 0.1 24.6 ± 0.1 <0.001
Smoking <0.001
Non-smoker 163(21.5%) 131(15.1%) 106(12.7%)
Ex-smoker 454(49.5%) 393(46.4%) 351(39.3%)
Current-smoker 205(29.0%) 276(38.5%) 345(48.0%)
Alcohol drinking <0.001
Non-drinker 375(45.7%) 238(27.1%) 138(17.5%)
Current-drinker1 447(54.3%) 562(72.9%) 664(82.5%)
Physical activity
Inactive 677(82.4%) 684(84.3%) 683(85.1%) 0.485
Active2 145(17.6%) 116(15.7%) 119(14.9%)
Tertile 1 (0 ~ 14 U/L) Tertile 2 (15 ~ 19 U/L) Tertile 3 (20 ~ 48 U/L)
Women (n = 3652) N = 1273 N = 1101 N = 1278
Age (years) 53.1 ± 0.4 55.6 ± 0.4 56.5 ± 0.4 <0.001
Body mass index (kg/m2) 22.9 ± 0.1 23.6 ± 0.1 24.7 ± 0.1 <0.001
Smoking 0.174
Non-smoker 1192(92.8%) 1019(91.9%) 1174(90.6%)
Ex-smoker 41(3.8%) 41(3.7%) 45(3.5%)
Current-smoker 40(3.4%) 41(4.4%) 59(5.8%)
Alcohol drinking 0.008
Non-drinker 913(68.9%) 741(62.6%) 831(62.3%)
Current-drinker1 360(31.1%) 360(37.4%) 447(37.7%)
Physical activity
Inactive 1079(86.1%) 964(87.9%) 1087(83.8%) 0.073
Active2 194(13.9%) 137(12.1%) 191(16.2%)
All statistics are results from complex survey data analyses.
1participants with alcohol drinking on one or more times of the past 30 days.
2participants with moderate or vigorous physical activity on 5 or more days of the past 7 days.
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statistically non-significant associations with IFG among
persons with serum GGT belonging to the 1st tertile of
the normal range. However, among persons with serum
GGT belonging to the 2nd or 3rd tertiles of the normal
range, the associations between BMI and IFG were
clearly observed, with adjusted ORs ranging from 2 to 4;
the P values for the multiplicative interactions were 0.032
for men and 0.059 for women. When we used waist
circumference as an index of obesity, the association
between waist circumference and IFG tended to become
stronger as serum GGT increased, especially among
women. However, the overall patterns of waist circumfer-
ence were weaker than those of BMI (see Additional file 1:
Table S1).When we repeated the same analyses with T2D as the
outcome measure, the patterns became weaker, and the
interaction terms failed to reach statistical significance
(see Additional file 1: Table S2). However, after exclusion
of known T2D, the associations between BMI and newly
diagnosed T2D became stronger as serum GGT increased,
similar to the results of IFG; however, the interaction
terms failed to reach statistical significance possibly due to
the small number of cases (see Additional file 1: Table S3).
When the associations between BMI and IFG were strati-
fied by levels of serum alanine aminotransferase (ALT) or
aspartate aminotransferase (AST), interactions with obes-
ity were not observed. BMI was strongly associated with
IFG in all strata of serum ALT or AST (see Additional
file 1: Table S4 and S5).
Table 2 Prevalence and adjusted odds ratios of impaired fasting glucose by tertile of serum γ-glutamyltransferase
(GGT) and category of body mass index (BMI)
Tertiles of serum GGT P trend
Men Tertile 1 (0 ~ 22 U/L) Tertile 2 (23 ~ 34 U/L) Tertile 3 (35 ~ 73 U/L)
Case/participants 184/822 240/800 315/802
Prevalence, % 19.5% 28.0% 39.4%
Odds ratio (95% CI)
Model 1 reference 1.6(1.2-2.2) 2.8(2.1-3.8) <0.001
Model 2 reference 1.4(1.0-1.9) 2.3(1.7-3.1) <0.001
Women Tertile 1 (0 ~ 14 U/L) Tertile 2 (15 ~ 19 U/L) Tertile 3 (20 ~ 48 U/L)
Case/participants 151/1273 226/1101 381/1278
Prevalence, % 10.9% 19.7% 28.8%
Odds ratio (95% CI)
Model 1 reference 1.9(1.4-2.5) 3.1(2.4-4.0) <0.001
Model 2 reference 1.8(1.3-2.3) 2.5(1.9-3.3) <0.001
Categories of BMI
<23 kg/m2 23-25 kg/m2 >25 kg/m2
Men
Case/participants 215/977 217/655 307/792
Prevalence, % 18.8% 32.5% 38.4%
Odds ratio (95% CI)
Model 1 reference 2.0(1.6-2.6) 2.7(2.2-3.4) <0.001
Model 2 reference 1.9(1.5-2.4) 2.3(1.8-2.9) <0.001
Women
Case/participants 211/1570 194/938 353/1144
Prevalence, % 12.4% 20.6% 29.3%
Odds ratio (95% CI)
Model 1 reference 1.7(1.3-2.3) 2.8(2.2-3.6) <0.001
Model 2 reference 1.6(1.2-2.1) 2.4(1.8-3.1) <0.001
All statistics, except case/participants, are results from complex survey data analyses.
Model 1: adjustment for age, smoking, alcohol intake, and physical activity.
Model 2: Further adjustment for BMI or GGT.
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reference group of men or women with serum GGT in
the lowest tertile and BMI < 23 kg/m2. Compared to this
reference group, the risk of IFG among men with BMI ≥
25 kg/m2 but serum GGT in the 1st tertile was 1.4 times
higher, but men with BMI ≥ 25 kg/m2 and serum GGT
in the 3rd tertile had about 5-fold increased risk of IFG.
This pattern was observed in women as well.
Discussion
In this study, we observed interactions between serum
GGT and BMI in relation to the risk of IFG in both men
and women. The associations between BMI and IFG were
different depending on the serum GGT levels within the
normal physiological range. Among persons belonging to
the lowest tertile of serum GGT, BMI showed statistically
non-significant weak associations with the risk of IFG.
However, for persons within the highest tertile of serumGGT, the risk of IFG was 3 − 4 times higher among
persons with BMI ≥ 25 kg/m2 than among those with
BMI < 23 kg/m2. Even though serum GGT itself is re-
ported to be related to IFG after adjusting for obesity in a
dose-response relationship [15-17], to the best of our
knowledge, this is the first study to evaluate whether or
not the well-established association between obesity and
IFG varies according to serum GGT levels.
The possibility of interactions between obesity and
serum GGT associated with the risk of T2D was suggested
in previous studies [3,5-10], but formal tests of multiplica-
tive interaction terms failed to reach statistical significance
in most studies [3,5,9,10]. Also, when gender-specific
analyses were performed in previous studies of T2D, only
women tended to show the interactions [6,8]. In fact,
when we compared the results of the two outcomes of
IFG and T2D in this study, the patterns were much
weaker with the outcome of T2D than with that of IFG.
Table 3 Prevalence and adjusted1 odds ratios of Impaired fasting glucose by category of body mass index (BMI) after
stratification by tertile of serum γ-glutamyltransferase (GGT)
BMI P trend P interaction
<23 kg/m2 23-25 kg/m2 >25 kg/m2
Men (n = 2424) 0.032
GGT tertile 1 (0 ~ 22 U/L)
Case/participants 95/447 45/204 44/171 0.193
Prevalence 17.2% 21.2% 23.4%
Adjusted OR (95% CI) reference 1.2(0.7-2.1) 1.4(0.8-2.3)
GGT tertile 2 (23 ~ 34 U/L)
Case/participants 66/297 71/213 103/290 0.001
Prevalence (%) 19.8% 31.4% 32.4%
Adjusted OR (95% CI) reference 1.9(1.2-3.1) 2.1(1.3-3.3)
GGT tertile 3 (35 ~ 73 U/L)
Case/participants 54/233 101/238 160/331 <0.001
Prevalence (%) 20.2% 42.0% 49.5%
Adjusted OR (95% CI) reference 2.9(1.8-4.8) 4.0(2.5-6.4)
Women (n = 3652) 0.059
GGT tertile 1 (0 ~ 14 U/L)
Case/participants 73/678 35/352 43/243 0.100
Prevalence (%) 9.8% 9.5% 15.8%
Adjusted OR (95% CI) reference 0.9(0.6-1.5) 1.7(1.0-2.8)
GGT tertile 2 (15 ~ 19 U/L)
Case/participants 66/491 65/262 95/348 <0.001
Prevalence (%) 13.2% 24.1% 26.0%
Adjusted OR (95% CI) reference 2.1(1.2-3.5) 2.2(1.4-3.5)
GGT tertile 3 (20 ~ 48 U/L) <0.001
Case/participants 72/401 94/324 215/553
Prevalence (%) 16.2% 29.7% 37.4%
Adjusted OR (95% CI) reference 2.1(1.3-3.2) 3.1(2.1-4.5)
All statistics, except the numbers of case/participants, are results from complex survey data analyses.
1Adjustment for age, smoking, alcohol intake, and physical activity.
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excluding known T2D, the patterns became somewhat
stronger than those of T2D but still weaker than those
of IFG. Therefore, as we hypothesized, the interaction
between obesity and serum GGT would appear in the
early stages of the pathogenesis of T2D and weaken
as the disease progressed.
The interactions between serum GGT and obesity in
relation to the risk of IFG suggest important pathophy-
siological mechanisms of T2D. In particular, the weak and
non-significant associations between obesity and IFG
among persons with very low normal serum GGT suggest
that obesity alone may be only a weak risk factor for de-
veloping IFG or T2D and that certain levels of serum
GGT within the normal range may be a prerequisite con-
dition for obesity to be strongly related to IFG or T2D.
Thus, the physiological functions of GGT should beconsidered to interpret this finding. At least three mecha-
nisms can be considered to explain this phenomenon:
GGT as an indicator of non-alcoholic fatty liver, which is
closely associated with obesity and visceral fat deposition
[18]; GGT as an early marker of oxidative stress [19]; or
GGT as a marker of low dose exposure to various chem-
ical mixtures [20].
However, the possibility that serum GGT showed such
interactions with obesity as a marker of non-alcoholic
fatty liver may be excluded because serum ALT, a sensitive
marker of non-alcoholic fatty liver [21], did not show in-
teractions with obesity in both the current and previous
study [7]. In addition, it is unlikely for serum GGT levels
belonging to the 2nd and 3rd tertiles of the normal range
to be related to any pathological condition in the liver.
Both experimental and clinical studies suggest that
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Figure 1 Adjusted odds ratios by tertiles (T) of serum γ-glutamyltransferase (GGT) and category of body mass index (BMI). BMI was
classified into 3 categories (<23, 23-25, and >25 kg/m2) and serum GGT was categorized into gender-specific tertiles. T1: first tertile; T2: second
tertile; T3: third tertile.
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tive stress in accumulated fat is an important mechan-
ism of the obesity-associated metabolic syndrome [23].
Therefore, if serum GGT within the normal range is a
marker of oxidative stress [19], the interactions between
serum GGT and obesity may be biologically plausible
because obese persons with elevated serum GGT can be
regarded as those at high risk of obesity-related diseases
due to oxidative stress. However, even though there are
many common biomarkers of oxidative stress in humans
[24], no published studies have evaluated the interac-
tions between these markers and obesity with regards to
the risk of T2D.
Another potential mechanism is that serum GGT may
be a marker of low dose exposure to chemical mixtures
because cellular GGT is a necessary enzyme to metabolize
glutathione conjugates of some environmental chemicals,
which is also closely related to oxidative stress [20].
Interestingly, there were interactions between persistent
organic pollutants (POPs), lipophilic chemical mixtures
stored in adipose tissue and continuously released to
circulation, and obesity in relation to the risk of T2D
[25-27], parallel to the findings of serum GGT and obesity;
the relationship between obesity and T2D became stron-
ger as the serum concentrations of POPs increased. In
particular, obesity was not associated with T2D among
persons with very low serum concentrations of POPs in
one human study [27]. Based on the physiological mech-
anism of the induction of cellular GGT and the empirical
findings on the interactions between POPs and obesity,
the claim of serum GGT as an indicator for various envir-
onmental chemicals seems to be the most plausible, and
the interactions between serum GGT and obesity suggest
that the presence of low dose chemical mixtures like POPsis necessary for T2D to develop, particularly in obese
persons.
Regardless of the mechanisms involved in the inter-
action between serum GGT and obesity, this finding has
an important clinical implication. In fact, individuals with
similar degrees of obesity can have strikingly different
risks of T2D [28]. For example, about 75–80% of obese
people never develop T2D even though 80% of patients
with T2D are obese [29]. Insulin resistance, a prediabetic
state, varies 6-fold among obese persons [30]. Thus, infor-
mation on serum GGT may be helpful to predict which
obese persons are at high risk of developing T2D.
This study has certain limitations. First, since this
study is a cross-sectional study, a causal relationship can-
not be established. However, previous studies with the
outcome of T2D, both prospective [3,5,8-10] and cross-
sectional [6,7] in design, showed the same tendency of the
interactions. Therefore, we expect that there is a similar
pattern with the incidence of IFG. In fact, cross-sectional
studies with the outcome of T2D, rather than IFG, can be
more complicated to interpret because patients with T2D
may try to lose weight, and serum GGT can also be af-
fected by changes in body weight [31]. Second, there may
be a misclassification bias due to the single measurement
of fasting glucose or serum GGT. However, the inaccuracy
of diagnosing IFG or classifying serum GGT may lead to a
non-differential misclassification, which would make the
true association weaker.
Conclusion
In conclusion, considering the current and previous find-
ings showing the different relationships of obesity with
IFG and T2D according to serum GGT levels within the
normal range, obesity itself may be only weakly associated
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lying factors that physiologically, but not pathologically,
induce increased serum GGT levels, may be more critical
factors in developing T2D, raising questions about the
current dogma regarding the association between obesity
and T2D. In addition, as the measurement of serum GGT
is easy and cheap, it could be used for early detection of
high-risk obese persons in the clinical field.
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